Biosynth Carbosynth Acquires Aalto Bio Reagents

Biosynth Carbosynth, a provider of life science research products and contract manufacturing services, has purchased Ireland-based Aalto Bio Reagents, a supplier of biological materials serving the in-vitro diagnostic (IVD) and vaccine development markets.  In March 2022, Biosynth acquired vivitide, a provider of custom peptides and antibodies.  Biosynth is backed by private equity firms KKR and Ampersand Capital.  Terms not announced.

Keywords: Healthcare Investment Banking, Healthcare M&A, Healthcare Mergers, Medical Devices, Biological Materials